Neoadjuvant therapy

The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy

Publication: Annals of Surgical Oncology, Sept 1 2023 Authors: Peter Blumencranz MD, FACS, Mehran Habibi MD, Steve Shivers PhD, Geza Acs MD, Lisa E. Blumencranz PhD, Erin B. Yoder MS, Bastiaan van der Baan MS, Andrea R. Menicucci PhD, Patricia Dauer PhD, William Audeh MD & Charles E. Cox MD

Read More
2024-02-16T06:56:48-08:00September 5th, 2023|Evidence, MINT, Neoadjuvant|

MammaPrint® Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2 breast cancer in NBRST

Publication: ASCO 2023, Abstract #521 Authors: Peter D. Beitsch 1 , James V. Pellicane 2 , Lajos Pusztai 3 , Paul L. Baron 4 , Erin F. Cobain 5 , Mary K. Murray 6 , Andrew Ashikari 7 , Pond R. Kelemen 7 , Angela Marie Mislowsky 8 , Julie Barone 9 , Kenneth H. Cowan 10 , Rakhshanda Layeequr Rahman 11 , William C. Dooley 12 , Andrea Menicucci 13 , Christine Carruth 13 , M. William Audeh 13 , Pat W. Whitworth 14 , NBRST Investigators Group

Read More
2024-02-16T06:58:05-08:00June 18th, 2023|Evidence, NBRST, Neoadjuvant|

DNA Repair Deficiency Biomarkers and the 70-Gene Ultra-High Risk Signature as Predictors of Veliparib/Carboplatin Response in the I-SPY 2 Breast Cancer Trial

PUBLICATION: NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. AUTHORS: Read More

2024-02-22T12:01:50-08:00March 1st, 2017|Evidence, ISPY-2, Neoadjuvant|

Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

PUBLICATION: Annals of Surgical Oncology; October 2014, Volume 21, Issue Read More

2024-02-20T10:41:05-08:00August 7th, 2014|Evidence, NBRST, Neoadjuvant|
Go to Top